Research Article
Bioavailability and Anticonvulsant Activity of 2-Cyanoguanidinophenytoin, a Structural Analogue of Phenytoin

https://doi.org/10.1021/js960093bGet rights and content

Abstract

Phenytoin is extensively used in Europe and the United States for the treatment of generalized tonic clonic seizures (grand mal). However, the efficacy is lowered by the erratic bioavailability after oral administration. The current study was conducted in order to investigate the physicochemical properties, the bioavailability, and the anticonvulsant activity of cyanoguanidinophenytoin (CNG-DPH), a structural analogue of phenytoin, which was obtained by the replacement of the urea moiety by a cyanoguanidine moiety. CNG-DPH was prepared under homogeneous Biltz conditions and under heterogeneous phase-transfer conditions. CNG-DPH is poorly water soluble and has a pKa of 5.3. At pH 7.4, log P′was 1.16, from which a pH-independent log P of 3 can be calculated. Pharmacokinetic parameters were obtained after oral administration of CNG-DPH to rats and were compared to those of phenytoin after administration of an equimolar amount. AUC, tmax, and Cmax were significantly increased compared to those of phenytoin. The anticonvulsant profile was similar to the profile of phenytoin. CNG-DPH was active in the maximal electroshock seizure test, albeit 7-fold less active than phenytoin. The analogue did not protect animals against convulsions induced by chemicals such as pentylenetetrazole, picrotoxin, N-methyl-aspartate, strychnine, and bicuculline. It is concluded that while the bioisosteric exchange of the urea moiety of the molecule with the cyanoguanidine moiety dramatically changed the physicochemical and pharmacokinetic parameters compared to those of phenytoin, the concomitant change of the affinity toward molecular targets reduced the pharmacological activity and the therapeutic efficacy of the compound.

References and Notes (32)

  • E. Shek

    Adv. Drug Delivery Rev.

    (1994)
  • S.A. Varia et al.

    J. Pharm. Sci.

    (1984)
  • Y. Yamaoka et al.

    J. Pharm. Sci.

    (1983)
  • C.H. Lee et al.

    J. Pharm. Sci.

    (1990)
  • S.J. Czuczwar et al.

    Eur. J. Pharmacol.

    (1985)
  • G.K.E. Scriba et al.

    J. Pharm. Sci.

    (1995)
  • V.J. Stella

    J. Pharm. Sci.

    (1977)
  • H. Bundgaard et al.

    Int. J. Pharm.

    (1980)
  • P.A. Schwartz et al.

    J. Pharm. Sci.

    (1977)
  • S.J. Agarwal et al.

    J. Pharm. Sci.

    (1968)
  • H.H. Merrit et al.

    J. Am. Med. Assoc.

    (1978)
  • R.L. Krall et al.

    Epilepsia

    (1978)
  • R.L. MacDonald et al.

    Epilepsia

    (1995)
  • T. Suzuki et al.

    Chem. Pharm. Bull.

    (1970)
  • K. Arnold et al.

    Can. J. Pharm Sci.

    (1970)
  • G.K.E. Scriba

    Arch. Pharm.

    (1993)
  • Cited by (10)

    View all citing articles on Scopus
    View full text